Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District (NSEC)

Background: Childhood epilepsy disorders are particular frequent in the area around Mahenge, southern Tanzania and recent studies have described a novel type of epilepsy with repetitive head nodding episodes and often progressive cognitive dysfunction. Despite the disease affecting thousands in Tanzania, Uganda and South Sudan, etiology and pathogenesis of the disorder termed Nodding Syndrome (NS) is still obscure as the phenotype remains imprecisely described. Epidemiological associations with Onchocerca volvulus and Mansonella spp. were noted at different African sites and remain robust even though no evidence for the presence of O. volvulus in CSF or any previous contact with the CSF was found.

Hypothesis: With regard to the complex host immune reaction to O. volvulus, the investigators hypothesize that the immune response against filariae might contribute to NS and epilepsy. The investigators further assume that specific genetic traits might play a role in the pathogenesis of NS.

Aims In the present study the investigators aim to examine if and how O. volvulus and/or Mansonella spp. contribute to the pathology of NS/epilepsy and therefore intend to analyze the filarial infection and the host immune response in affected children. To identify inherited traits predisposing for epilepsy, NS or specific immune responses, a genetic workup that includes whole-exome sequencing (WES) is performed. The clinical and EEG characteristics are further defined. Cognitive impairment of people with epilepsy and NS is assessed using the Wechsler Nonverbal Scale of Ability (WNV).

Study design: A cross-sectional observational (groups I-III) and a case-control (groups I-V) study recruiting in total 250 patients and controls (I: people with NS, n=50; II: people with epilepsy (PWE) and onchocerciasis, n=50; III: PWE without onchocerciasis, n=50; IV: controls with onchocerciasis but otherwise healthy, n= 50; healthy controls without evidence for onchocerciasis, n= 50) is performed to describe the clinical characteristics in children with NS/epilepsy and to evaluate differences in infection and immune response between groups, respectively. The WNV should be validated in 500 healthy controls to obtain reference data in rural Africa.

Summary: In summary, the study aims to elucidate clinical characteristics and the pathogenesis of NS/epilepsy in children of southern Tanzania and role of parasitic infection as a cause for NS/epilepsy.

Study Overview

• Status: Unknown
• Conditions: Epilepsy; Cognitive Impairment; Onchocerciasis; Nodding Syndrome
• Intervention / Treatment: Other: no intervention

Detailed Description

Childhood epilepsy disorders are particular frequent in low income countries and especially common in the area around Mahenge, Ulanga region, southern Tanzania, with an epilepsy prevalence of up to 39 per 1000 inhabitants. Therefore, in 1959 Prof. Louise Jilek-Aall founded the Mahenge Epilepsy Clinic to provide basic care to people suffering from convulsive disorders and to enable further in-depth investigations regarding epilepsy. In the summer of 2005, a multinational a team of researchers including the founder of the clinic, Prof. Louise Jilek-Aall, Prof. Erich Schmutzhard, Dr. Andrea Winkler and Prof. William Matuja performed several in-depth etiological investigations. In intensive field research they were able to examine a large number of clinic patients and healthy controls, perform electro-encephalographic and magnetic resonance studies and collect biological materials, such as blood, cerebrospinal fluid (CSF) and skin samples for further sophisticated laboratory tests in Europe. Among others, the studies confirmed the presence of a new type of childhood epilepsy with repetitive head nodding episodes and often progressive cognitive dysfunction. Even though the disease termed Nodding Syndrome (NS) affects thousands in Tanzania, Uganda and South-Sudan, clinical, metabolic and EEG phenotypes are still imprecisely described, and etiology and pathogenesis remain obscure. The high familial occurrence and clustering within circumscribed villages and tribes suggests that genetic traits might play a role. Epidemiological associations with Onchocerca volvulus and Mansonella spp. were noted at different African sites. Despite lacking evidence for the presence of O. volvulus in the CSF the association to NS remains robust.

This is basis for the present study where the investigators aim to examine if and how O. volvulus and/or Mansonella spp. contribute to the pathology of NS, elucidate associated genetic traits, further specify the clinical, metabolic and EEG phenotypes. The investigators will use a cross-sectional observational design including children with NS and epilepsy in order to describe the clinical characteristics and a case-control design to evaluate associated factors.

It is intended to enroll 250 patients and controls between 3 and 18 years of age (I: people with NS, n=50 (inclusion according to the WHO case definition from the first "International Conference on Nodding Syndrome", Kampala, Uganda, July 2012); II: people with epilepsy (PWE) and onchocerciasis, n=50; III: PWE without onchocerciasis, n=50; IV: controls with onchocerciasis but otherwise healthy, n= 50; healthy controls without evidence for onchocerciasis, n= 50). Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, lacking or withdrawing consent will be excluded. Groups II to V will be matched to Group I for age, gender and social status.

The investigators intend to analyze the filarial infection and host immune response in affected children compared to unaffected controls. PCR assays will be performed to characterize Onchocerca and Mansonella spp. strains found in patients with NS/PWE and determine Wolbachia loads and features. A novel unique biomarker, N-acetyltyramine-O,ß-glucuronide (NATOG) will be determined to quantify infection with O. volvulus and correlated with other markers that define the host immune response and immune regulation (e.g. regulatory T cells (Treg), cytokines). As polymorphisms in the multidrug-resistance gene 1 (MDR-1) that alter p-glycoprotein expression or function may enhance neurotoxicity of widely used antihelmintic drugs, single nucleotide polymorphism (SNP)-arrays will be determined to investigate if specific polymorphisms might be associated with NS. In addition, the investigators aim to define the clinical picture and course of NS and conduct further EEG investigations and validated neuropsychological tests, follow up patients of previous studies and perform metabolic analyses to specify the metabolic characteristics of NS. A genetic workup that includes whole-exome sequencing (WES) to identify traits predisposing to epilepsy, NS or specific immune responses is scheduled.

In summary, the study aims to elucidate factors that contribute to the high prevalence of NS and epilepsy in the Mahenge area in Southern Tanzania. Also, the research project will have immediate benefits for the population under investigation as people newly diagnosed with epilepsy will be offered treatment at the Mahenge Epilepsy Clinic and staff, patients and relatives will receive further education regarding epilepsy, thereby contributing to sustainability of a standardized approach to care for children with NS and PWE. Conclusions drawn from our study will not only relate to the Mahenge area, but may be applicable to vast numbers of children with NS (northern Uganda and South Sudan) and PWE in other areas. Dissemination of the data through scientific meetings and publications may stimulate further research regarding risk factors for epilepsy in the low income countries.

• Study Type: Observational
• Enrollment (Anticipated): 250

Contacts and Locations

Study Locations

• Tanzania
  • Mahenge, Tanzania
    • Recruiting
    • Mahenge Epilepsy Clinic
    • Contact: William Matuja, Professor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 97 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

With support of the hospital staff, participants aged 3 to 99 years will be recruited consecutively among the registered patients as they are seen once a month for a clinical check-up and to receive their medication. Suitable relatives of patients will also be asked to take part in the study.

The study groups with their respective inclusion criteria are defined above. Patients of group I-III will be first recruited into the cross-sectional study and subsequently into the case-control study. Groups II to VI will be matched to Group I for age, gender, social status and stay within the Mahenge area.

Description

I) Patients with Nodding syndrome confirmed or suspected Case of Nodding syndrome (according to the WHO epidemiologic surveillance case definition: reported head nodding in a previously healthy person with at least 2 major and 1 minor criteria Major criteria Age 3 to 18 y at onset of head nodding Nodding frequency 5 to 20 times per min Minor criteria Other neurologic abnormalities (cognitive decrease, school dropout due to cognitive or behavioral problems, other seizures or neurologic abnormalities) Clustering in space or time with similar cases Triggering by eating or cold weather Delayed sexual or physical development Psychiatric manifestations

As agreed upon at the first International Conference on Nodding Syndrome, Kampala, Uganda, July 2012 (16). EEG,

II) People with epilepsy (PWE) and onchocerciasis confirmed or clinically suspected generalized and idiopathic epilepsy confirmed active infection with O. volvulus (microscopy, PCR and serology)

III) People with epilepsy (PWE) without onchocerciasis confirmed or clinically suspected generalized and idiopathic epilepsy excluded active or past infection with O. volvulus (microscopy, PCR and serology)

IV) Controls with onchocerciasis, otherwise healthy no evidence for epilepsy or other neurological diseases confirmed active infection with O. volvulus (microscopy, PCR and serology)

V) Controls without onchocerciasis, otherwise healthy no evidence for epilepsy or other neurological diseases excluded active or past infection with O. volvulus (microscopy, PCR and serology)

VI) Healthy controls for cognitive assessment, matched to Groups I to V

inclusion criteria: The study groups with their respective inclusion criteria are defined above.

Patients of group I-III will be first recruited into the cross-sectional study and subsequently into the case-control study. Groups II to VI will be matched to Group I for age, gender, social status and stay within the Mahenge area.

exlusion criteria: Patients with evidence for co-infections with HIV, Tb, Malaria or other parasites, cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

6

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Nodding syndrome; I) probable Case of Nodding Syndrom (according to the "WHO epidemiologic surveillance case definition") *reported head nodding ** in a previously healthy person with at least 2 major and 1 minor criteria Major criteria; Age 3 to 18 y at onset of head nodding; Nodding frequency 5 to 20 times per min Minor criteria; Other neurologic abnormalities; Clustering in space or time with similar cases; Triggering by eating or cold weather; Delayed sexual or physical development; Psychiatric manifestationsAs agreed upon at the first International Conference on Nodding Syndrome, Kampala, Uganda, July 2012 (16). ** Repetitive involuntary drops of the head toward the chest on >2 occasions.	Other: no intervention; no intervention
epilepsy and onchocerciasis; II) People with epilepsy (PWE) and onchocerciasis (n= 50); confirmed or suspected generalized and idiopathic epilepsy; confirmed active infection with O. volvulus (microscopy, PCR and serology) Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded.	Other: no intervention; no intervention
epilepsy, no onchocerciasis; III) People with epilepsy (PWE) without onchocerciasis (n= 50); confirmed or suspected generalized and idiopathic epilepsy; excluded active or past infection with O. volvulus (microscopy, PCR and serology) Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded.	Other: no intervention; no intervention
no epilepsy but onchocerciasis; IV) Controls with onchocerciasis, otherwise healthy (n= 50); no evidence for epilepsy or other neurological diseases; confirmed active infection with O. volvulus (microscopy, PCR and serology) Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded.	Other: no intervention; no intervention
no epilepsy, no onchocerciasis; V) Healthy Controls without onchocerciasis (n= 50); no evidence for epilepsy or other neurological diseases; excluded active or past infection with O. volvulus (microscopy, PCR and serology) Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded.	Other: no intervention; no intervention
controls for Wechsler Nonverbal (WNV); Healthy Controls for cognitive assessment only, (n= 750) no evidence for epilepsy or other neurological diseases no detailled examination on O. volvulus performed Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded.	Other: no intervention; no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Describing clinical features in children with Nodding Syndrome and other forms of epilepsy e.g. characteristics of the seizures, EEG abnormalities and reporting co-morbidities and impairments.	Obtaining clinical features and medical history. Comparing medical history, Seizure types and -frequency and other clinical Features between the groups.	2014-2018
Describing EEG features in children with Nodding Syndrome and other forms	Performing EEG recordings and comparing EEG abnormalities (numbers, types and site of epileptiform discharges (ED), background alterations) between the groups.	2014-2018

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measuring the rate of filarial infections in patients with NS, epilepsy and controls.	Performing skin snip microscopy and PCR analysis to detect O. volvulus and Mansonella spp. in patients with NS, epilepsy and controls.	2014-2018
Characterization of O. volvulus in patients with Nodding Syndrome and epilepsy.		2014-2018
Characterization of the host immune response to O. volvulus.		2014-2018
Analyzing for genetic traits associated with epilepsy, NS, enhanced Ivermectin toxicity or specific immune responses.	Performing a genetic workup for known monogenetic forms of epilepsy, single nucleotide polymorphisms (SNP) associated with enhanced Ivermectin toxicity and adverse immune reactions. Performing a Whole-exome sequencing (WES) with biomedical analysis.	2014-2018
Measuring the cognitive impairment in patients with NS and epilepsy.	Using the Wechsler Nonverbal Scale of Ability (WNV) and comparing the results to matched healthy controls.	2014-2018

Collaborators and Investigators

• Sponsor: Heidelberg University

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2014
• Primary Completion (Anticipated): May 1, 2019
• Study Completion (Anticipated): May 1, 2019

Study Registration Dates

• First Submitted: January 25, 2017
• First Submitted That Met QC Criteria: August 28, 2018
• First Posted (Actual): August 31, 2018

Study Record Updates

• Last Update Posted (Actual): August 31, 2018
• Last Update Submitted That Met QC Criteria: August 28, 2018
• Last Verified: August 1, 2018

More Information

Terms related to this study

• Keywords: Epilepsy; Cognitive impairment; Onchocerciasis; Nodding Syndrome; Head Nodding; Mahenge
• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Skin Diseases; Infections; Epilepsy, Generalized; Neurocognitive Disorders; Disease; Parasitic Diseases; Skin Diseases, Parasitic; Skin Diseases, Infectious; Cognition Disorders; Spirurida Infections; Secernentea Infections; Nematode Infections; Helminthiasis; Filariasis; Epilepsy; Syndrome; Cognitive Dysfunction; Onchocerciasis; Nodding Syndrome
• Other Study ID Numbers: HD-DZIF-MUHAS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No